OTC Reporter Mid-Day Alert for Thursday 7-29-10
Mid-Day Alert for Thursday 7-29-2010
Keep your eye on MBHS, this could be a good bounce play opportunity.
Just about a month ago MBHS was trading at .39 almost 100% up from its current level. With the recent acquisition of Skin Cancer Scanning, Ltd , MBHS could be taken to a whole new level!
Possible Bounce - MBHS
Skin Cancer Scanning Ltd. is a medical device company pioneering the
development and commercialization of a revolutionary and proprietary imaging
system for the early detection and diagnosis of skin cancer.
Percentage Gainer- NMTI
http://www.chartmoney.com/stockcharts.php/stockcharts.php/?ticker=nmti&B1=Get+Chart
NMT Medical, Inc., a medical technology company, designs, develops, manufactures, and markets implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive catheter-based procedures.
http://www.chartmoney.com/stockcharts.php/stockcharts.php/?ticker=nmti&B1=Get+Chart
NMT Medical, Inc., a medical technology company, designs, develops, manufactures, and markets implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive catheter-based procedures.
News Alert- CYTR
http://finance.yahoo.com/news/CytRxs-Tamibarotene-bw-3545079261.html?x=0&.v=1
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that an advanced form of acute promyelocytic leukemia, or APL, has been eradicated in former NBA player Ray Johnston following treatment with CytRx’s experimental cancer drug tamibarotene.
http://finance.yahoo.com/news/CytRxs-Tamibarotene-bw-3545079261.html?x=0&.v=1
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that an advanced form of acute promyelocytic leukemia, or APL, has been eradicated in former NBA player Ray Johnston following treatment with CytRx’s experimental cancer drug tamibarotene.
OTCReporter.com, HotOTCChina.com, OTCPennystockreporter.com,
OTCPennypicks.com, and Chartpenny.com (the “Websites”) are owned by Oceanic
Consulting, LLC ("Oceanic") and Garden State Resources NJ, LLC ("Garden State")
(Oceanic and Garden State are collectively referred to herein as the "LLC
Companies) , both of which are New Jersey limited liability
corporations (the Websites and its owners, the LLC Companies, and their
affiliates, directors and officers and its immediate family members are referred
to in our Disclaimer as "OTCR" or "we" or "us" or "our"). Because we receive
monetary or securities compensation, most often in the form of
common stock (hereafter referred to as the "Shares") for our dissemination of
publicly disseminated information (the “Information”) regarding various issuers
of securities, we disclose our specific compensation herein and in our
individual reports of profiled issuers. The LLC Companies received forty thousand dollars from a non-affiliate third
party shareholder of MBHS Skin Cancer Scanning Ltd. in return for OTCR’s
services to publicly and electronically disseminate information pertaining to
Skin Cancer Scanning Ltd. It is imperative that
all readers of the above compenstations disclosure carefully review our
Disclaimer in its entirety, which contains important information about penny
stocks, our operations, the limited nature of the Information and various risks
attendant to the companies that we profile, including that: (a) we receive our
compensation in free trading shares, which we will sell immediately upon their
receipt as well as during the dissemination of such Information or within hours,
days, weeks or months thereafter, or at any time; as a result, our selling
activities will cause significant volatility in the Issuer’s stock price and/or
significantly depress the Issuer’s stock price; (b) we will buy and sell the
Shares in the open market before, during or after the dissemination of the
Information or at any time, which will cause significant volatility in the
Issuer’s stock price and/or significantly depress or increase the Issuer’s stock
price; (c) there is an inherent and actual conflict of interest that exists
between our Readers’ interests and our interests because we: (i) receive the
Shares as compensation for disseminating the Information and thereafter sell
those Shares at any time for monetary gain, including at the same time the
Information is being disseminated or shortly thereafter or at any time; and (ii)
buy and sells the Profiled Company’s shares in the open market at the same time
or before the Information is being disseminated or shortly after the
dissemination of the Information or at any time. Our gains from sale of the
Shares may be substantial.
|
Manage your subscription
|